175 related articles for article (PubMed ID: 35793834)
21. Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Masri S; Lui K; Phung S; Ye J; Zhou D; Wang X; Chen S
Breast Cancer Res Treat; 2009 Aug; 116(3):461-70. PubMed ID: 18677558
[TBL] [Abstract][Full Text] [Related]
22. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
Miki Y; Suzuki T; Hatori M; Igarashi K; Aisaki KI; Kanno J; Nakamura Y; Uzuki M; Sawai T; Sasano H
Bone; 2007 Apr; 40(4):876-87. PubMed ID: 17254854
[TBL] [Abstract][Full Text] [Related]
23. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.
Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
Clin Cancer Res; 2004 Sep; 10(17):5717-23. PubMed ID: 15355898
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms of glutathione S-transferase A1 and O1 and breast cancer among postmenopausal Danish women.
Olsen A; Autrup H; Sørensen M; Overvad K; Tjønneland A
Eur J Cancer Prev; 2008 Jun; 17(3):225-9. PubMed ID: 18414193
[TBL] [Abstract][Full Text] [Related]
25. Neoplastic effects of exemestane in premenopausal breast cancer model.
Kubatka P; Sadlonova V; Kajo K; Machalekova K; Ostatnikova D; Nosalova G; Fetisovova Z
Neoplasma; 2008; 55(6):538-43. PubMed ID: 18999884
[TBL] [Abstract][Full Text] [Related]
26. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.
Cigler T; Richardson H; Yaffe MJ; Fabian CJ; Johnston D; Ingle JN; Nassif E; Brunner RL; Wood ME; Pater JL; Hu H; Qi S; Tu D; Goss PE
Breast Cancer Res Treat; 2011 Apr; 126(2):453-61. PubMed ID: 21221773
[TBL] [Abstract][Full Text] [Related]
27. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
Kim I; Keam B; Lee KH; Kim JH; Oh SY; Ra EK; Yoon SS; Park SS; Kim CS; Park S; Hong YC; Kim BK
Clin Transplant; 2007; 21(2):207-13. PubMed ID: 17425746
[TBL] [Abstract][Full Text] [Related]
28. Combined GSTM1-Null, GSTT1-Active, GSTA1 Low-Activity and GSTP1-Variant Genotype Is Associated with Increased Risk of Clear Cell Renal Cell Carcinoma.
Coric VM; Simic TP; Pekmezovic TD; Basta-Jovanovic GM; Savic Radojevic AR; Radojevic-Skodric SM; Matic MG; Dragicevic DP; Radic TM; Bogdanovic LM; Dzamic ZM; Pljesa-Ercegovac MS
PLoS One; 2016; 11(8):e0160570. PubMed ID: 27500405
[TBL] [Abstract][Full Text] [Related]
29. Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S15-8. PubMed ID: 11970744
[TBL] [Abstract][Full Text] [Related]
30. Modulation of human serum glutathione S-transferase A1/2 concentration by cruciferous vegetables in a controlled feeding study is influenced by GSTM1 and GSTT1 genotypes.
Navarro SL; Chang JL; Peterson S; Chen C; King IB; Schwarz Y; Li SS; Li L; Potter JD; Lampe JW
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2974-8. PubMed ID: 19900941
[TBL] [Abstract][Full Text] [Related]
31. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
[TBL] [Abstract][Full Text] [Related]
32. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G
Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846
[TBL] [Abstract][Full Text] [Related]
33. Examination of the use of Exemestane in patients with metastatic breast cancer.
Takashima S; Kiyoto S; Takahashi M; Hara F; Takabatake D; Aogi K; Ohsumi S
Breast Cancer; 2011 Jul; 18(3):189-94. PubMed ID: 21437667
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Campone M; Beck JT; Gnant M; Neven P; Pritchard KI; Bachelot T; Provencher L; Rugo HS; Piccart M; Hortobagyi GN; Nunzi M; Heng DY; Baselga J; Komorowski A; Noguchi S; Horiguchi J; Bennett L; Ziemiecki R; Zhang J; Cahana A; Taran T; Sahmoud T; Burris HA
Curr Med Res Opin; 2013 Nov; 29(11):1463-73. PubMed ID: 23962028
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Burris HA; Lebrun F; Rugo HS; Beck JT; Piccart M; Neven P; Baselga J; Petrakova K; Hortobagyi GN; Komorowski A; Chouinard E; Young R; Gnant M; Pritchard KI; Bennett L; Ricci JF; Bauly H; Taran T; Sahmoud T; Noguchi S
Cancer; 2013 May; 119(10):1908-15. PubMed ID: 23504821
[TBL] [Abstract][Full Text] [Related]
36. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer.
Nakajima T; Elovaara E; Anttila S; Hirvonen A; Camus AM; Hayes JD; Ketterer B; Vainio H
Carcinogenesis; 1995 Apr; 16(4):707-11. PubMed ID: 7728947
[TBL] [Abstract][Full Text] [Related]
37. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Yamamoto Y; Ishikawa T; Hozumi Y; Ikeda M; Iwata H; Yamashita H; Toyama T; Chishima T; Saji S; Yamamoto-Ibusuki M; Iwase H
BMC Cancer; 2013 May; 13():239. PubMed ID: 23679192
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Ikeda M; Kurebayashi J; Sonoo H; Miyake A; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K
Gan To Kagaku Ryoho; 2008 Feb; 35(2):261-5. PubMed ID: 18281762
[TBL] [Abstract][Full Text] [Related]
39. Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: An extensive preclinical investigation.
Rizwanullah M; Perwez A; Alam M; Ahmad S; Mir SR; Rizvi MMA; Amin S
Int J Pharm; 2023 Jul; 642():123136. PubMed ID: 37311498
[TBL] [Abstract][Full Text] [Related]
40. Association between glutathione S-transferase A1, M1 and T1 polymorphisms and hypertension.
Oniki K; Hori M; Takata K; Yokoyama T; Mihara S; Marubayashi T; Nakagawa K
Pharmacogenet Genomics; 2008 Mar; 18(3):275-7. PubMed ID: 18300949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
